EPISODE · Dec 19, 2012 · 7 MIN
Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma
from Journal of Clinical Oncology (JCO) Podcast
A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.
NOW PLAYING
Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m